Phase I study of concurrent selective lymph node late course accelerated hyper-fractionated radiotherapy and Capecitabine, Cisplatin for locally advanced esophageal squamous cell carcinoma.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 19733411.
- Also identified by DOI 10.1016/j.radonc.2009.08.002.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Twelve patients with locally advanced esophageal squamous cell carcinoma were enrolled to evaluate the safety and efficacy of concurrent chemo-radiotherapy. Dose-limiting toxicity was mainly observed at Capecitabine 1500 mg. The maximum-tolerated dose/recommended dose of Capecitabine was 1000 mg. The Kaplan-Meier estimated overall l-year survival rate was 100%.
Medical subject headings
- Antineoplastic Combined Chemotherapy Protocols
- Carcinoma, Squamous Cell
- Dose Fractionation, Radiation
- Esophageal Neoplasms
- Lymphatic Irradiation